Corbus CRB-913 Hits 5% Weight Loss in Phase 1b Obesity Trial With Clean Safety
CRBP sits 30% above its 52-week low of $7.12 on elevated volume (4.8× avg).
Summary
Corbus announced positive Phase 1b obesity data for CRB-913 showing 5% placebo-adjusted weight loss at 12 weeks with a clean psychiatric and GI safety profile, positioning it as a potential new class of oral non-incretin obesity medicines.
Key Events · Product Development and Regulatory · CRBP
-
CRB-913 Achieves 5% Weight Loss
CANYON-1 Phase 1b trial (n=254) showed 5.0% placebo-adjusted mean weight loss at 60 mg after 12 weeks (p<0.0001), with dose-dependent efficacy (2.8% at 20 mg, 3.3% at 40 mg) and no plateauing.
-
Clean Safety Profile
No serious or severe psychiatric AEs, no suicidality, and only one moderate depressive symptom across 188 dosed participants. GI AEs markedly lower than oral GLP-1s: vomiting 1.6% vs 31% for oral semaglutide 25 mg.
-
Late-Breaker at ObesityWeek 2026
Full dataset selected for late-breaking presentation at ObesityWeek 2026, November 14-17, 2026 in Washington, DC.
-
Phase 2 Start Planned 1H 2027
Company plans to engage FDA on clinical development and initiate a Phase 2 monotherapy study in the first half of 2027; also evaluating combination with GLP-1 therapy.
Analysis · CRBP · Life Sciences
Corbus reported positive topline data from its CANYON-1 Phase 1b trial of CRB-913, an oral CB1 inverse agonist for obesity. The 60 mg dose achieved 5.0% placebo-adjusted mean weight loss at 12 weeks with no plateauing, statistically significant at all three doses. The safety profile is the differentiator: no serious or severe psychiatric AEs, no suicidality, and GI tolerability markedly better than oral GLP-1s (vomiting 1.6% vs 31% for oral semaglutide 25 mg). This validates the peripheral-restriction hypothesis that has plagued prior CB1 drugs like monlunabant, which was discontinued for psychiatric side effects. For a $157M market-cap biotech burning cash, this de-risks the obesity program and supports a Phase 2 start in 1H 2027. The data was selected for a late-breaking presentation at ObesityWeek 2026 in November.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1179 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRBP was trading at $9.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $157.1M. The 52-week trading range was $7.12 to $20.56. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.